Literature DB >> 18454252

The ubiquitin-proteasome pathway in Huntington's disease.

Steven Finkbeiner1, Siddhartha Mitra.   

Abstract

The accumulation of mutant protein is a common feature of neurodegenerative disease. In Huntington's disease, a polyglutamine expansion in the huntingtin protein triggers neuronal toxicity. Accompanying neuronal death, mutant huntingtin aggregates in large macromolecular structures called inclusion bodies. The function of the machinery for intracellular protein degradation is linked to huntingtin toxicity and components of this machinery colocalize with inclusion bodies. An increasing body of evidence implicates the ubiquitin-proteasome pathway in the failure of cells to degrade mutant huntingtin. A number of potential mechanisms that link compromised ubiquitin-proteasome pathway function and neurodegeneration have been proposed and may offer opportunities for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454252      PMCID: PMC2637619          DOI: 10.1100/tsw.2008.60

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  114 in total

1.  Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

Authors:  A Yamamoto; J J Lucas; R Hen
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

Review 2.  Aging and regulated protein degradation: who has the UPPer hand?

Authors:  Vita A Vernace; Thomas Schmidt-Glenewinkel; Maria E Figueiredo-Pereira
Journal:  Aging Cell       Date:  2007-08-06       Impact factor: 9.304

3.  Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry.

Authors:  David M Smith; Shih-Chung Chang; Soyeon Park; Daniel Finley; Yifan Cheng; Alfred L Goldberg
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

4.  In vivo disassembly of free polyubiquitin chains by yeast Ubp14 modulates rates of protein degradation by the proteasome.

Authors:  S Swaminathan; B A Krantz; K D Wilkinson; M Hochstrasser
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

Review 5.  Recent insights into the molecular pathogenesis of Huntington disease.

Authors:  B R Leavitt; C L Wellington; M R Hayden
Journal:  Semin Neurol       Date:  1999       Impact factor: 3.420

6.  Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.

Authors:  A Wyttenbach; J Carmichael; J Swartz; R A Furlong; Y Narain; J Rankin; D C Rubinsztein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 7.  Glutamine repeats and neurodegeneration.

Authors:  H Y Zoghbi; H T Orr
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

Review 8.  BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.

Authors:  D A Fennell; A Chacko; L Mutti
Journal:  Oncogene       Date:  2007-09-10       Impact factor: 9.867

9.  Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.

Authors:  Farasat Zaman; Victoria Menendez-Benito; Emma Eriksson; Andrei S Chagin; Masaharu Takigawa; Bengt Fadeel; Nico P Dantuma; Dionisios Chrysis; Lars Sävendahl
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

10.  Global changes to the ubiquitin system in Huntington's disease.

Authors:  Eric J Bennett; Thomas A Shaler; Ben Woodman; Kwon-Yul Ryu; Tatiana S Zaitseva; Christopher H Becker; Gillian P Bates; Howard Schulman; Ron R Kopito
Journal:  Nature       Date:  2007-08-09       Impact factor: 49.962

View more
  30 in total

1.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

Review 2.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

3.  Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture.

Authors:  Xuan Zhang; Erik R Abels; Jasmina S Redzic; Julia Margulis; Steve Finkbeiner; Xandra O Breakefield
Journal:  Cell Mol Neurobiol       Date:  2016-03-07       Impact factor: 5.046

Review 4.  Huntington's Disease.

Authors:  Steven Finkbeiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

5.  Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.

Authors:  Bin Tang; Tamara Seredenina; Giovanni Coppola; Alexandre Kuhn; Daniel H Geschwind; Ruth Luthi-Carter; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2011-02-18       Impact factor: 5.996

Review 6.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

7.  Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP.

Authors:  Hui Yang; Chao Liu; Yongwang Zhong; Shouqing Luo; Mervyn J Monteiro; Shengyun Fang
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

Review 8.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

9.  Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.

Authors:  Haiqun Jia; Ryan J Kast; Joan S Steffan; Elizabeth A Thomas
Journal:  Hum Mol Genet       Date:  2012-09-10       Impact factor: 6.150

Review 10.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.